Alliance Entertainment (Nasdaq: AENT) appointed longtime licensing and retail strategist Brian Maggio as VP of Sales for its fast-growing Handmade by Robots™ brand. Known for its whimsical, knit-inspired vinyl collectibles, the brand is gaining momentum across major retailers and fan communities—now poised for its next growth phase under Maggio’s leadership, as the collectibles market continues to thrive across mass and specialty channels.

Greenwich LifeSciences (Nasdaq: GLSI) has completed enrollment of the 250-patient open label arm in its Phase III FLAMINGO-01 trial evaluating GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence. This milestone strengthens the company’s clinical foundation in non-HLA-A*02 patients—who represent over half of the eligible population—as it analyzes recurrence and immune response data ahead of potential regulatory discussions to expand the trial design.

NioCorp (Nasdaq: NB) drew nearly 600 attendees—including Nebraska Governor Jim Pillen, U.S. Senators, and EXIM leadership—to a pair of packed town halls showcasing overwhelming support for its Elk Creek Critical Minerals Project. With federal and state leaders hailing the project as vital to U.S. national security and supply chain resilience, NioCorp enters 2026 with accelerating momentum as it advances toward construction of one of America’s most strategically significant critical minerals deposits.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) is doubling its sales force, launching a new GoodRx partnership, and enhancing digital marketing for ARAKODA® after a 6-month commercial pilot showed rising prescriber demand. With momentum building in malaria prevention, the company is also adding clinical sites to its ongoing babesiosis trials, following FDA guidance on its Breakthrough Therapy Designation request.